3W69
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | ROTATING ANODE |
Source details | RIGAKU MICROMAX-007 HF |
Temperature [K] | 100 |
Detector technology | IMAGE PLATE |
Collection date | 2007-03-02 |
Detector | RIGAKU RAXIS VII |
Wavelength(s) | 1.54178 |
Spacegroup name | P 21 21 21 |
Unit cell lengths | 53.562, 65.761, 81.436 |
Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
Resolution | 21.180 - 1.900 |
R-factor | 0.21038 |
Rwork | 0.209 |
R-free | 0.23810 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 1rv1 |
RMSD bond length | 0.013 |
RMSD bond angle | 2.127 |
Data reduction software | PROCESS |
Data scaling software | SCALA |
Phasing software | MOLREP |
Refinement software | REFMAC (5.2.0019) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 44.800 | 2.000 |
High resolution limit [Å] | 1.900 | 1.900 |
Rmerge | 0.069 | 0.475 |
Number of reflections | 22162 | |
<I/σ(I)> | 8.3 | 1.5 |
Completeness [%] | 95.5 | 95.2 |
Redundancy | 2.1 | 2 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, SITTING DROP | 8.1 | 293 | 2.4M Ammonium sulfate, 5% PEG 200, 0.1M Tris HCl, pH 8.1 , VAPOR DIFFUSION, SITTING DROP, temperature 293K |